Daniela Börnigen

Daniela Börnigen

Auto-generated profile, based on publicly available information

Daniela Börnigen

Department of Cardiology Hamburg (C.S., F.M.O., F.S., R.R., D.B., D.A., R.B.S., S.B.), University Medical Center Hamburg-Eppendorf, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
MOMarek Ostaszewski
Marek Ostaszewski
Anna NiarakisAnna Niarakis
Anna Niarakis
AMAlexander Mazein
Alexander Mazein
IKInna Kuperstein
Inna Kuperstein
RPRobert Phair
Robert Phair
RSReinhard Schneider
Reinhard Schneider
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS‐CoV‐2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large‐scale community effort to build an open access, interoperable and computable repository of COVID‐19 molecular mechanisms. The COVID‐19 Disease Map (C19DMap) is a graphical, interactive representation of disease‐relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph‐based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS‐CoV‐2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID‐19 or similar pandemics in the long‐term perspective.

17 May 2016 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
FOFrancisco M. Ojeda
Francisco M. Ojeda
CMChristian Mueller
Christian Mueller
DBDaniela Börnigen
Daniela Börnigen
DTDavid-Alexandre Trégouët
David-Alexandre Trégouët
ASArne Schillert
Arne Schillert
RSRenate B. Schnabel
Renate B. Schnabel
Prognostic models based on survival data frequently make use of the Cox proportional hazards model. Developing reliable Cox models with few events relative to the number of predictors can be challenging, even in low-dimensional datasets, with a much larger number of observations than variables. In such a setting we examined the performance of methods used to estimate a Cox model, including (i) full model using all available predictors and estimated by standard techniques, (ii) backward elimination (BE), (iii) ridge regression, (iv) least absolute shrinkage and selection operator (lasso), and (v) elastic net. Based on a prospective cohort of patients with manifest coronary artery disease (CAD), we performed a simulation study to compare the predictive accuracy, calibration, and discrimination of these approaches. Candidate predictors for incident cardiovascular events we used included clinical variables, biomarkers, and a selection of genetic variants associated with CAD. The penalized methods, i.e., ridge, lasso, and elastic net, showed a comparable performance, in terms of predictive accuracy, calibration, and discrimination, and outperformed BE and the full model. Excessive shrinkage was observed in some cases for the penalized methods, mostly on the simulation scenarios having the lowest ratio of a number of events to the number of variables. We conclude that in similar settings, these three penalized methods can be used interchangeably. The full model and backward elimination are not recommended in rare event scenarios.

1 December 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
MOMarek Ostaszewski
Marek Ostaszewski
Anna NiarakisAnna Niarakis
Anna Niarakis
AMAlexander Mazein
Alexander Mazein
IKInna Kuperstein
Inna Kuperstein
RPRobert Phair
Robert Phair
RSReinhard Schneider
Reinhard Schneider
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS‐CoV‐2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large‐scale community effort to build an open access, interoperable and computable repository of COVID‐19 molecular mechanisms. The COVID‐19 Disease Map (C19DMap) is a graphical, interactive representation of disease‐relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph‐based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS‐CoV‐2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID‐19 or similar pandemics in the long‐term perspective.

7 August 2025 in Journal of Medical Virology
Verified
Journal Article
Open access
SDSusanne Caroline Duwe
Susanne Caroline Duwe
DODjin-Ye Oh
Djin-Ye Oh
MWMarianne Wedde
Marianne Wedde
DBDaniela Börnigen
Daniela Börnigen
RIRalf Ignatius
Ralf Ignatius
RDRalf Dürrwald
Ralf Dürrwald
The first waves of the COVID‐19 pandemic were accompanied by an unprecedented decrease of influenza activity which persisted throughout the 2020/21 and 2021/22 winter seasons. Here, we report on the unusual influenza circulation patterns that followed in the year 2022, which was dominated throughout by A(H3N2) influenza viruses. After a delayed spring wave in 2022, A(H3N2) influenza viruses circulated at low levels throughout the summer and rose to a prominent, prematurely‐timed fall/winter wave peaking in December, with highest positivity rates observed in 10–12‐years old children. This winter wave ended abruptly with the national school holidays, when positivity rates decreased sharply not only in children but also in other age groups. Genetic analysis of influenza virus hemagglutinin (HA) showed cocirculation of 10 A(H3N2) clades, of which three (2a.1b, 2a.3a.1, and 2b) became dominant in late 2022. All A(H3N2) viruses, including those assigned to the new clades, displayed high titers in HA inhibition tests with postinfection ferret antiserum raised against the A(H3N2) vaccine strains A/Cambodia/e0826360/2020 and A/Darwin/9/2021. All viruses were susceptible to neuraminidase inhibitors and the polymerase inhibitor baloxavir marboxil, but carried the M2‐S31N substitution conferring adamantane resistance. Our findings shed light on disturbed seasonality of A(H3N2) circulation in the post‐COVID‐19 era.

28 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MOMarek Ostaszewski
Marek Ostaszewski
Anna NiarakisAnna Niarakis
Anna Niarakis
AMAlexander Mazein
Alexander Mazein
IKInna Kuperstein
Inna Kuperstein
RPRobert Phair
Robert Phair
RSReinhard Schneider
Reinhard Schneider
We describe a large-scale community effort to build an open-access, interoperable, and computable repository of COVID-19 molecular mechanisms - the COVID-19 Disease Map. We discuss the tools, platforms, and guidelines necessary for the distributed development of its contents by a multi-faceted community of biocurators, domain experts, bioinformaticians, and computational biologists. We highlight the role of relevant databases and text mining approaches in enrichment and validation of the curated mechanisms. We describe the contents of the Map and their relevance to the molecular pathophysiology of COVID-19 and the analytical and computational modelling approaches that can be applied for mechanistic data interpretation and predictions. We conclude by demonstrating concrete applications of our work through several use cases and highlight new testable hypotheses.

1 November 2026 in Stroke
Verified
Journal Article
Closed access
CSChristian Schulte
Christian Schulte
FOFrancisco M. Ojeda
Francisco M. Ojeda
MJMärit Jensen
Märit Jensen
FSFerdinand Seum
Ferdinand Seum
RRRené Riedel
René Riedel
TZTanja Zeller
Tanja Zeller
BACKGROUND: Stratification of stroke risk remains challenging, but metabolomic profiling offers the potential to detect new biomarkers and to improve early risk assessment of incident stroke. The objective of this study was to evaluate the association between circulating metabolites and the incidence of stroke in a case-cohort study conducted across several large population-based European cohorts. METHODS: Following the case-cohort design, a subset of 10 299 individuals, including all individuals with incident stroke, was selected from the original cohort of >70 000 individuals. The case-cohort design used a random subsample of the selected population cohorts, supplemented with cases not sampled in this random subcohort. A total of 141 circulating metabolites were measured from serum samples of the selected individuals, and associations of these metabolites with risk of incident stroke were estimated and compared with those of classic risk factors (sex, age at examination, systolic blood pressure, total cholesterol, body mass index, diabetes, daily smoking status, and antihypertensive treatment). Associations with time to stroke were assessed using weighted Cox proportional hazards models adjusted for the classic risk factors. Hazard ratios (HRs) for the log-transformed metabolites were reported per 1 SD increase. RESULTS: Of the 70 195 individuals in the original cohort, 1516 (2.2%) experienced incident strokes during a median follow-up time of 8.9 years (interquartile range, 4.4–14.7). Median age was 56.8 years (interquartile range, 49.5–62.4), and 39.5% were women. Six of the 141 metabolites (2 diacyl-phosphatidylcholines, 2 lyso-phosphatidylcholines, 1 hydroxysphingomyelin, and glutamic acid) remained significantly associated with incident stroke after correction for multiple comparisons (adjusted HRs [95% CIs] per SD: lyso-phosphatidylcholines a C18:2 HR, 0.88 [95% CI, 0.82–0.93], lyso-phosphatidylcholines a C17:0 HR, 0.88 [95% CI, 0.83–0.94], hydroxysphingomyelin C14:1 HR, 0.90 [95% CI, 0.85–0.94], diacyl-phosphatidylcholines C34:1 HR, 1.10 [95% CI 1.05–1.16], diacyl-phosphatidylcholines C32:1 HR, 1.14 [95% CI, 1.08–1.21], glutamic acid HR, 1.23 [95% CI 1.11–1.37]). The strengths of these associations were similar to those for classic cardiovascular risk factors (C statistics for 10-year prediction ranging from 0.782 to 0.785 for metabolites compared with 0.781 to 0.792 for classic cardiovascular risk factors). CONCLUSIONS: Among 10 299 individuals from the general European population, we identified 6 metabolites from 4 different metabolite classes that were associated with future risk of stroke. The application of specific circulating metabolites may improve early stroke risk prediction before the onset of potentially irreversible cerebrovascular pathological processes.